Axim Biotechnologies, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 10/06/2017
Contact Info
  • 45 Rockefeller Plaza
  • 20th Floor
  • Suite 83
  • New York, NY 10111

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0001514946
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. 2010
Employees Not Available
Company Officers/Contacts
George E. Anastassov CEO, President
Robert Malasek CFO
Lekhram Changoer CTO
Philip A. Van Damme Chief Scientific Officer
Company Directors
George E. Anastassov Chairman
Timothy R Scott Director, Audits
Lekhram Changoer
Robert Cunningham
Philip A. Van Damme
John W Huemoeller II
Blake N. Schroeder
Company Notes
  • Formerly=Axim International Inc until 7-2014
Service Providers
Accounting/Auditing Firm
805 Third Avenue
Suite 902
New York, NY, 10022
United States

Legal Counsel
Phillip E. Koehnke, APC
PO Box 235472
Encinitas, CA, 92024
United States

Investor Relations Firm
102 Madison Avenue
12th Floor
New York, NY, 10016
United States

AXIM Security Details
Share Structure
Market Value1 $339,072,894 a/o Nov 16, 2017
Authorized Shares 300,000,000 a/o Sep 30, 2016
Outstanding Shares 52,569,441 a/o May 19, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 35,206,500 a/o Jan 23, 2017
Par Value 0.0001
Shareholders of Record 50 a/o Apr 17, 2017
Short Selling Data
Short Interest 35,134 (-34.97%)
Oct 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security